Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2020

View Archived Issues

Degradation approach targets extracellular proteins

Honest placebos change brain potentials

Phase II trial of VIR-2218 plus peg-IFN-alfa 2a recruits patients with HBV infection

Genentech opens phase I study of GDC-6036 KRAS G12C mutation solid tumors

PDE5 inhibitor AR-1001 affects mechanisms involved in Alzheimer's disease

Cadila Healthcare patents NLRP3 inflammasome inhibitors

Further signs of efficacy seen in trial of AstroRx in amyotrophic lateral sclerosis

Roche patents new HBV antivirals

Nanjing TransThera Biosciences identifies AOC3 inhibitors

Innovative phase III study assesses LY-CoV555 for preventing SARS-CoV-2 infection in care facilities

French researchers disclose TfR1-targeting antibodies

Novartis synthesizes mTORC1 inhibitors

Encouraging topline phase III results reported for seladelpar in primary biliary cholangitis

Tasquinimod treatment begins in phase Ib/IIa multiple myeloma study

Alzheimer's blood test could improve trials, help find treatments

Phase II study begun for Zhifei Longcom's recombinant coronavirus vaccine

Data presented for factor XIa inhibitor milvexian in thrombosis models

FDA approves IND for phase II study of varoglutamstat in Alzheimer's disease

Variants in CD55 gene may cause protein-losing enteropathy

NTR-441 developed to clear neutrophil extracellular traps in severe cases of COVID-19

Spravato antidepressant nasal spray approved in the U.S. for MDD with suicidal ideation

Phase II study evaluates BMS-986278 in lung fibrosis

FDA issues complete response letter for Viaskin Peanut

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...